Vol 7, Supplement 7 (August 2018): Translational Cancer Research

Editorial

Tumor-mesenchymal stem cell interactions: therapeutic implications for epithelial ovarian cancer
Alain Piché
Circular RNA HIPK3: an emerging player in diabetes
Xiaoyun He, Chibin Pu, Yongsheng Quan, Chunlin Ou, Suxian Zhou
Identification of two cancer-associated fibroblast markers revealing stromal heterogeneity in sustaining cancer progression and chemoresistance
Alexia Brunel, Rémi Samain, Cindy Neuzillet, Corinne Bousquet
Immature CML cells implement a BMP autocrine loop to escape TKI treatment
Mohammad Houshmand, Paola Circosta, Giuseppe Saglio
circRNAs and miRNAs in the diagnosis of hepatocellular carcinoma: the long race to new targets
Silvia Fittipaldi, Francesco Vasuri
Casein kinase 1: a new tale of chronic lymphocytic leukemia (CLL) microenvironment
Stefania Fiorcari, Rossana Maffei, Roberto Marasca
Identification of optimal reference RNAs to normalize miRNA expression data by qRT-PCR in formalin-fixed, paraffin-embedded lymph node tissue
Eliana Bignotti, Paola Todeschini, Chiara Romani
Large cohort observational study integrates current knowledge on changes in outcome for melanoma brain metastases in tyrosine kinase inhibitor (TKI)-immunotherapy era
Stefano Vagge, Andrea Riccardo Filippi
Prediagnostic genetic stratification for aggressive prostate cancer—is the puzzle for genetic variants gaining shape?
Marco Randazzo, Orlando Burkhardt
Are lung adenocarcinoma mutations shaping the immune microenvironment?
Philippe Rochigneux, Edward B. Garon
Role of polygenic hazard score in prostate-specific antigen (PSA) screening for prostate cancer
Ning Shao, Yao Zhu, Dingwei Ye
Circular RNA and exosomes in pancreatic cancer progression
Takahiro Seimiya, Motoyuki Otsuka, Hung-Yin Liu, Tatsunori Suzuki, Kazuma Sekiba, Mari Yamagami, Eri Tanaka, Rei Ishibashi, Kazuhiko Koike
Epigenetic regulator ARID1A and stem cell transcription factor SOX9 in the maintenance of pancreatic ductal cell differentiation state and development of intraductal papillary mucinous neoplasia (IPMN) and pancreatic ductal adenocarcinoma (PDAC)
Naipeng Cui, Jinsong Zhang, Huatian Huang, Lingeng Lu
Editorial response to “Clinical complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study”
Yair Lotan
Editorial on “PNLDC1 is essential for piRNA 3' end trimming and transposon silencing during spermatogenesis in mice”
Zachary T. Dye, Paul W. Dyce
Circular RNAs: an emerging type of non-coding RNA and their potential implications in bladder cancer
Amelia Cimmino, Valerio Costa, Daniela Terracciano, Matteo Ferro
Editorial on “The genomic landscape of TERT promoter wildtype-IDHwildtype glioblastoma”
Rui Batista, Tiago Bordeira Gaspar, Paula Soares, João Vinagre
The urea cycle enzymes act as metabolic suppressors in clear cell renal cell carcinoma
Giuseppe Lucarelli, Matteo Ferro, Pasquale Ditonno, Michele Battaglia
Tumor mutation burden as emerging biomarker in non-small cell lung cancer and beyond
Rieke N. Fischer, Jürgen Wolf
Immunotherapy in non-small cell lung cancer: steps towards more effective combination therapies
Matthew W. Rosenbaum, Mari Mino-Kenudson
Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
Kartik Sehgal, Rushad Patell, Deepa Rangachari, Daniel B. Costa
An expanding role for osimertinib for the treatment of ErbB family driven NSCLC
Anthony C. Faber, Timothy F. Burns
Crizotinib in ROS1-positive non-small cell lung cancer: an Asian large phase II trial confirms its key-role
Paolo Maione, Cesare Gridelli
Additive effects of atezolizumab and bevacizumab plus chemotherapy for patients with non-small cell lung cancer regardless of presence of EGFR mutations, ALK rearrangements, or PD-L1 expression
Takehiro Uemura, Toyoaki Hida
Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts
Kristopher A. Lyon, Jason H. Huang